Analysts at UBS AG increased their price target on shares of Biogen Idec (NASDAQ: BIIB) from $167.00 to $200.00 in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports. The firm currently has a “neutral” rating on the stock.
A number of other analysts have also recently weighed in on BIIB. Analysts at Bank of America reiterated a “neutral” rating on shares of Biogen Idec in a research note to investors on Thursday. They now have a $187.00 price target on the stock, up previously from $182.00. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Biogen Idec in a research note to investors on Thursday. They now have a $200.00 price target on the stock, up previously from $187.00. Finally, analysts at Goldman Sachs reiterated a “buy” rating on shares of Biogen Idec in a research note to investors on Thursday. They now have a $211.00 price target on the stock, up previously from $190.00.
Ten equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $182.71.
Shares of Biogen Idec (NASDAQ: BIIB) traded down 0.12% during mid-day trading on Monday, hitting $192.38. Biogen Idec has a 52 week low of $124.23 and a 52 week high of $192.92. The stock’s 50-day moving average is currently $171.0. The company has a market cap of $45.462 billion and a P/E ratio of 33.44.
Biogen Idec (NASDAQ: BIIB) last issued its quarterly earnings data on Monday, January 28th. The company reported $1.40 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.46 by $0.06. The company had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.38 billion. During the same quarter in the previous year, the company posted $1.51 earnings per share. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. Biogen Idec has set its FY13 guidance at $7.15-7.25 EPS. Analysts expect that Biogen Idec will post $7.68 EPS for the current fiscal year.
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders.